Cargando…
ADPase CD39 Fused to Glycoprotein VI‐Fc Boosts Local Antithrombotic Effects at Vascular Lesions
BACKGROUND: GPVI (Glycoprotein VI) is the essential platelet collagen receptor in atherothrombosis. Dimeric GPVI‐Fc (Revacept) binds to GPVI binding sites on plaque collagen. As expected, it did not increase bleeding in clinical studies. GPVI‐Fc is a potent inhibitor of atherosclerotic plaque‐induce...
Autores principales: | Degen, Heidrun, Borst, Oliver, Ziegler, Melanie, Mojica Munoz, Ann‐Katrin, Jamasbi, Janina, Walker, Britta, Göbel, Silvia, Fassbender, Julia, Adler, Kristin, Brandl, Richard, Münch, Götz, Lorenz, Reinhard, Siess, Wolfgang, Gawaz, Meinrad, Ungerer, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586441/ https://www.ncbi.nlm.nih.gov/pubmed/28751543 http://dx.doi.org/10.1161/JAHA.117.005991 |
Ejemplares similares
-
The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke
por: Goebel, Silvia, et al.
Publicado: (2013) -
Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke
por: Reimann, Andreas, et al.
Publicado: (2016) -
Cross-Linking GPVI-Fc by Anti-Fc Antibodies Potentiates Its Inhibition of Atherosclerotic Plaque- and Collagen-Induced Platelet Activation
por: Jamasbi, Janina, et al.
Publicado: (2016) -
The GPVI – Fc Fusion Protein Revacept Reduces Thrombus Formation and Improves Vascular Dysfunction in Atherosclerosis without Any Impact on Bleeding Times
por: Ungerer, Martin, et al.
Publicado: (2013) -
Differential Inhibition of Human Atherosclerotic Plaque–Induced Platelet Activation by Dimeric GPVI-Fc and Anti-GPVI Antibodies: Functional and Imaging Studies
por: Jamasbi, Janina, et al.
Publicado: (2015)